Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Shared discovery and development R&D expenses by Year
Shared discovery and development R&D expenses ($M) ($M)
Moderna Shared discovery and development R&D expenses: $797M in FY2025, down 30.4% from a year earlier.
Latest, FY2025
797
Period ended Dec 31, 2025
Change on a year earlier
-30.4%
1,145 in FY2024
History
8 years
Since FY2018
Sources
5
Documents cited below
Where the FY2025 figure comes from
“Shared discovery and development expenses | 797 | 1,145 | 789”
Source: FY2025 10-K ↗
Reported in Form 10-K / 10-Q Item 7 (MD&A R&D Breakdown).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Shared discovery and development R&D expenses ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 797 | -30.4% | FY2025 10-K ↗ |
| FY2024 | Dec 31, 2024 | 1,145 | +45.1% | FY2025 10-K ↗ |
| FY2023 | Dec 31, 2023 | 789 | +41.9% | FY2025 10-K ↗ |
| FY2022 | Dec 31, 2022 | 556 | +129.8% | FY2024 10-K ↗ |
| FY2021 | Dec 31, 2021 | 242 | +105.1% | FY2023 10-K ↗ |
| FY2020 | Dec 31, 2020 | 118 | +100.0% | FY2021 10-K ↗ |
| FY2019 | Dec 31, 2019 | 59 | +33.3% | FY2021 10-K ↗ |
| FY2018 | Dec 31, 2018 | 44.3 | – | FY2020 10-K ↗ |
Cite this data
StockData. (2026). Moderna Shared discovery and development R&D expenses ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-shared-discovery-dev
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.